These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38669256)

  • 1. The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence.
    Buchynska L; Gordiienko I; Glushchenko N; Iurchenko N
    PLoS One; 2024; 19(4):e0302075. PubMed ID: 38669256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
    Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
    Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
    Abdel-Fatah TM; Middleton FK; Arora A; Agarwal D; Chen T; Moseley PM; Perry C; Doherty R; Chan S; Green AR; Rakha E; Ball G; Ellis IO; Curtin NJ; Madhusudan S
    Mol Oncol; 2015 Mar; 9(3):569-85. PubMed ID: 25468710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
    Lee LJ; Ratner E; Uduman M; Winter K; Boeke M; Greven KM; King S; Burke TW; Underhill K; Kim H; Boulware RJ; Yu H; Parkash V; Lu L; Gaffney D; Dicker AP; Weidhaas J
    PLoS One; 2014; 9(4):e94167. PubMed ID: 24732316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
    Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
    Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
    Stewart CJ; Amanuel B; Grieu F; Carrello A; Iacopetta B
    J Clin Pathol; 2010 Jul; 63(7):604-8. PubMed ID: 20591910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
    Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
    Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
    Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
    Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
    Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
    Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
    Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of KRAS in Endometrial Cancer: A Mini-Review.
    Sideris M; Emin EI; Abdullah Z; Hanrahan J; Stefatou KM; Sevas V; Emin E; Hollingworth T; Odejinmi F; Papagrigoriadis S; Vimplis S; Willmott F
    Anticancer Res; 2019 Feb; 39(2):533-539. PubMed ID: 30711927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
    Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
    Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
    van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
    Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
    Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R
    Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.
    Engelsen IB; Mannelqvist M; Stefansson IM; Carter SL; Beroukhim R; Øyan AM; Otte AP; Kalland KH; Akslen LA; Salvesen HB
    Br J Cancer; 2008 May; 98(10):1662-9. PubMed ID: 18475299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma.
    Yoo SH; Park BH; Choi J; Yoo J; Lee SW; Kim YM; Kim KR
    Mod Pathol; 2012 Nov; 25(11):1496-507. PubMed ID: 22766790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.